Seattle Children's Hospital Research Institute - Center for Global Infectious Disease Research

Darren Flatley

🇮🇹 Italy

9

Reviewed: February 4, 2024

• - Biomarker Development
• - 12 weeks October 2023 - January 2024
• - Research Institution

The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.

Maxine Kuhlman II

🇬🇧 United Kingdom

9.3

Reviewed: September 14, 2023

• - Project Management
• - 10 weeks July - September 2023
• - Biotech Company

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Saul Schuppe

🇯🇵 Japan

8.6

Reviewed: October 2, 2023

• - Patient Engagement
• - 8 weeks August - September 2023
• - Clinical Research Organization

The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.

Randal Kerluke

🇷🇺 Russia

6.5

Reviewed: July 18, 2024

• - Regulatory Submission
• - 8 weeks May - July 2024
• - Pharmaceutical Company

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Nettie Nikolaus-Schimmel

🇺🇸 United States

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Mr. Gene Kautzer

🇮🇳 India

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.